CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 18 enrolled
Drug / intervention
CBD and THC with GT4 technologycombination
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05121506
NCT05121506Phase 1Completed

A Single-arm Open-label Study to Investigate the Bioavailability and Skin Absorption of CBD and THC From GT4 Technology in Healthy Adults

Gefion Canada Inc.·interventional·Posted Nov 16, 2021·Updated Jun 1, 2022

In Brief

A Phase 1 clinical trial evaluating CBD and THC with GT4 technology for Biological Availability and 3 related conditions. Completed, enrolled 18 participants across 1 site.

Detailed Summary

The bioavailability of cannabinoids differs greatly for different routes of administration. When applied topically to the skin, they are absorbed through the skin or hair follicles while interacting with receptors to provide localized effects. To gain more information on the potential of this route of administration in therapeutic applications, this open-label study will investigate the skin absorption and bioavailability of CBD and THC delivered trans-dermally.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada
CollaboratorsKGK Science Inc.

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedNov 16, 2021
Enrollment StartNov 27, 2021
Primary CompletionJan 18, 2022
TodayJul 1, 2026
Enrollment to primary: 2 monthsPosted 4.6 years ago

Interventions

CBD and THC with GT4 technologycombination

A single topical dose of CBD and THC will be administered with GT4 technology. The material will be provided in a single use pre-filled syringe.